Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.-Reference-Cited by-同舟云学术

Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.

Published:1996-03-01 Issue:3 Volume:38 Page:430-438
ISSN:0017-5749
Container-title:Gut
language:en
Short-container-title:Gut

Author:

Arnold R,Trautmann M E,Creutzfeldt W,Benning R,Benning M,Neuhaus C,Jurgensen R,Stein K,Schafer H,Bruns C,Dennler H J

Publisher

BMJ

Subject

Gastroenterology

Reference44 articles.

1. Therapeutic strategies in the management of endocrine GEP tumours;Arnold, R.;EurJ Clin Invest,1990

2. Treatment of metastatic islet cell carcinoma with a somatostatin analogue;Kvols, L.K.; Buck, M.; ChG, Moertel; Schutt, A.J.; Rubin, J.; O'Connell, M.J.;Ann Intern Med,1987

3. Use of long-acting somatostatin analogue SMS 201-995 in patients with pancreatic islet-cell tumours;Maton, P.N.; Gardner, J.D.; Jensen, R.T.;Dig Dis Sci,1989

4. Effects of sandostatin on neuro-endocrine tumours of the gastrointestinal system;Buchanan, K.D.;Recent Results Cancer Res,1993

5. Treatment of gastrointestinal endocrine tumours with interferon-alpha and octreotide;Creutzfeldt, W.; Bartsch, H.H.; Jacubaschke, U.; St6ckmann, F.;Acta Oncol,1991

Cited by 316 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The global leadership into malnutrition criteria reveals a high percentage of malnutrition which influences overall survival in patients with gastroenteropancreatic neuroendocrine tumours;Journal of Neuroendocrinology;2024-02-22

2. From biology to clinical practice: antiproliferative effects of somatostatin analogs in neuroendocrine neoplasms;Therapeutic Advances in Medical Oncology;2024-01

3. Quantitative uptake in 99mTc-EDDA/HYNIC-TOC somatostatin receptor imaging – the effect of long-acting release somatostatin analogue therapy;Nuclear Medicine Communications;2023-08-14

4. Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [18F]SiTATE;Frontiers in Oncology;2023-01-30

5. Evaluation of survival outcomes in patients with sporadic, advanced, unresectable well-differentiated pancreatic neuroendocrine tumors treated initially with octreotide LAR and subsequent therapeutical approaches on relapse. A real-world data set;Oncology in Clinical Practice;2022-10-28